Press Releases

Promore Pharma has enrolled first patient in HEAL LL-37 in Poland

Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland

Promore Pharma Plans to Expand Indications of Therapeutic Peptide PXL01 in the Field of Dermal Scarring

Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland

Interim report January – June 2018

Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2018

Promore Pharma receives approval for Phase IIb trial with LL-37

Report from the Annual General Meeting of Promore Pharma AB held on 16 May 2018

Promore Pharma AB (publ) Interim report January – March 2018

Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2018

Promore Pharma Out-licenses PXL01 for Spinal Surgery to PharmaResearch Products Ltd

Promore Pharma 2017 Annual report published

Västra Hamnen Corporate Finance Initiates Coverage on Promore Pharma

Notice of Annual General Meeting in Promore Pharma AB (publ)

Promore Pharma Regains Rights for PXL01 Manufacturing

Year-end report 2017

Promore Pharma is granted a patent for PXL01 in the US

Promore Pharma Adjusts Plans for PXL01 in North America

Interim report January – September 2017

Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060

Promore Pharma Signs Agreement with CRO PCG Clinical Services

Promore Pharma Completes Extensive European Collaboration Regarding DPK-060

Promore Pharma Signs Manufacturing Agreement with APL

Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days

Interim report January – June 2017

Promore Pharma starts trading on Nasdaq First North on 6 July 2017

Promore Pharma awaiting approval from Nasdaq First North in next week

New share issue in Promore Pharma raises 76 MSEK ahead of listing on Nasdaq First North

Promore Pharma Carries Out a Share Issue Prior to Listing on Nasdaq First North

Interim report January – March 2017

Promore Pharma AB files phase III clinical trial application in India

Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO

Promore Pharma and Cellastra Inc. Announce Phase III Clinical Collaboration to Develop Therapeutic Peptide PXL01 for the US Market

Promore Pharma Announces a Strategic Collaboration with Technomark Life Sciences

Lipopeptide AB Announces a Strategic Collaboration with Pharmaresearch Products LTD

Pergamum AB Announces Ownership Restructuring

Pergamum Announces Final Data from Phase I/II Study in Patients with Chronic Leg Ulcers

Pergamum Reports Positive Follow-Up Data from a Phase II Clinical Trial of PXL01 for Prevention of Post-Surgical Adhesions

Pergamum Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd.